CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 493 enrolled
Drug / intervention
Dietressa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01535014
NCT01535014Phase 3Completed
CompareCT.gov

Multicentric Double-blind Placebo-controlled Randomized Parallel-group Clinical Trial of Safety and Efficacy of Various Dosage Schedules for Dietressa Drug in Treatment of Obese Patients

Materia Medica Holding·interventional·Posted Feb 17, 2012·Updated Nov 28, 2018

In Brief

A Phase 3 clinical trial evaluating Dietressa and Placebo for Obesity. Completed, enrolled 493 participants across 17 sites.

Detailed Summary

The purpose of this study is: * To assess safety of Dietressa in the dose of 6 tablets daily within 24 weeks in treatment of obese patients. * To assess clinical efficacy of Dietressa in the dose of 6 tablets daily within 24 weeks of therapy in reducing body weight in obese patients. * To compare clinical efficacy of two dosage patterns for Dietressa (1 tablet 6 times daily and 2 tablets 3 times daily) within 24 weeks in treatment of obese patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity
CountriesRussia
Collaborators--

Timeline

Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedFeb 17, 2012
Enrollment StartDec 12, 2011
Primary CompletionJun 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.4 years ago

Interventions

Dietressadrug

Comparison of different dosages (frequency) of drug

Placebodrug

Placebo either (2 tablets 3 times daily) or (1 tablet 6 times daily)